Genscript Biotech Corporation (GNNSF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNNSF steht fuer Genscript Biotech Corporation, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 58/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Genscript Biotech Corporation (GNNSF) Gesundheitswesen & Pipeline-Uebersicht
Genscript Biotech Corporation is a global biotechnology company focused on life science research products and services, biologics development, industrial synthetic biology, and cell therapy. With a presence in North America, Europe, Asia Pacific, and China, Genscript serves diverse sectors, including pharmaceuticals, diagnostics, and agriculture.
Investmentthese
Genscript Biotech Corporation presents a notable research candidate within the biotechnology sector, driven by its diverse service offerings and global reach. Key value drivers include the continued expansion of its biologics development services and the growth of its cell therapy segment, particularly in the development of CAR-T therapies. The company's established presence in key markets like North America, Europe, and China provides a solid foundation for future growth. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. Investors should monitor the progress of Genscript's clinical trials and its ability to maintain a competitive edge in the rapidly evolving biotechnology landscape.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Genscript Biotech Corporation operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
- The company was founded in 2002 and is headquartered in Nanjing, China.
- Genscript Biotech Corporation has a market capitalization of $3.41 billion as of 2026-03-17.
- The company employs 5568 individuals.
- Genscript Biotech Corporation serves customers in North America, Europe, the People's Republic of China, Japan, and other Asia Pacific regions.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse service offerings across multiple segments of the biotechnology industry.
- Global presence and established customer base.
- Proprietary technologies and intellectual property.
- Strong reputation and brand recognition.
Schwaechen
- Reliance on outsourced research and development spending.
- Exposure to regulatory risks and uncertainties.
- Competition from established players in the biotechnology industry.
- Dependence on key personnel and scientific expertise.
Katalysatoren
- Upcoming: Progress in clinical trials for cell therapy candidates.
- Ongoing: Expansion of biologics development services.
- Ongoing: Penetration of industrial synthetic biology products.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Strategic partnerships and acquisitions.
Risiken
- Potential: Regulatory hurdles and delays in drug approvals.
- Potential: Competition from established players in the biotechnology industry.
- Potential: Economic downturn and reduced research and development spending.
- Ongoing: Technological obsolescence and disruption.
- Ongoing: Dependence on key personnel and scientific expertise.
Wachstumschancen
- Expansion of Biologics Development Services: Genscript can capitalize on the increasing demand for biologics development services by expanding its capabilities in antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development. The global biologics market is projected to reach $457 billion by 2026, presenting a significant growth opportunity for Genscript. Timeline: Ongoing.
- Growth in Cell Therapy Segment: The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth due to its potential in treating liquid and solid tumors. Genscript's focus on discovering and developing CAR-T therapies positions it to benefit from this trend. The global CAR-T therapy market is expected to reach $4.9 billion by 2027. Timeline: Ongoing.
- Penetration of Industrial Synthetic Biology Products: Genscript can expand its presence in the industrial synthetic biology market by developing and producing industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The global industrial enzymes market is projected to reach $7.0 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
- Geographic Expansion: Genscript can further expand its global presence by penetrating new geographic markets, particularly in emerging economies with growing healthcare sectors. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Genscript can pursue strategic partnerships and acquisitions to expand its service offerings, access new technologies, and strengthen its market position. These partnerships can provide access to complementary expertise and resources, accelerating growth and innovation. Timeline: Ongoing.
Chancen
- Expansion of biologics development services.
- Growth in cell therapy segment.
- Penetration of industrial synthetic biology products.
- Strategic partnerships and acquisitions.
Risiken
- Economic downturn and reduced research and development spending.
- Technological obsolescence and disruption.
- Increased competition and price pressure.
- Adverse regulatory changes and clinical trial failures.
Wettbewerbsvorteile
- Proprietary technologies and intellectual property in gene synthesis and protein engineering.
- Established reputation and brand recognition in the life science research market.
- Global presence and extensive customer base.
- Integrated service offerings across multiple segments of the biotechnology industry.
Ueber GNNSF
Founded in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation has evolved into a key player in the life science industry. The company operates through four distinct segments. The Life Science Services and Products segment offers a range of research services, including gene synthesis, molecular cloning, and antibody development, catering to basic biology studies, pharmaceutical discovery, and disease diagnostics. The Biologics Development Services segment provides antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development for pharmaceutical, biotech, government, and academic clients. The Industrial Synthetic Biology Products segment focuses on constructing non-pathogenic microbial strains and producing industrial enzymes for the food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment is dedicated to discovering and developing chimeric antigen receptor T-cell therapies for treating liquid and solid tumors. Genscript's global presence spans North America, Europe, China, Japan, and other Asia Pacific regions, serving a diverse customer base across various industries.
Was das Unternehmen tut
- Provides gene synthesis and molecular cloning services.
- Offers oligonucleotide synthesis services.
- Specializes in protein engineering and peptide synthesis.
- Develops and produces antibody development services.
- Creates molecular diagnostics tools.
- Offers genome editing materials.
- Develops chimeric antigen receptor T-cell therapies.
Geschaeftsmodell
- Provides fee-for-service research and development services to pharmaceutical and biotechnology companies.
- Sells life science research products, including reagents, kits, and instruments.
- Develops and commercializes cell therapies for the treatment of cancer.
- Generates revenue through licensing agreements and royalties.
Branchenkontext
Genscript Biotech Corporation operates within the rapidly growing biotechnology industry, driven by increasing demand for advanced research tools, biologics development services, and cell therapies. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Genscript's diverse service offerings and global presence position it to capitalize on the increasing demand for outsourced research and development services from pharmaceutical and biotechnology companies. The company's focus on cell therapy also aligns with the growing interest in personalized medicine and innovative cancer treatments.
Wichtige Kunden
- Pharmaceutical companies
- Biotechnology companies
- Government research institutions
- Academic research institutions
- Food and chemical industries
Finanzdaten
Chart & Info
Genscript Biotech Corporation (GNNSF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer GNNSF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GNNSF.
Kursziele
Wall-Street-Kurszielanalyse fuer GNNSF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GNNSF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Weihui Shao
Unknown
Information on Weihui Shao's background is not available in the provided data. Details regarding his career history, education, and previous roles are currently unknown. Further research would be required to provide a comprehensive profile.
Erfolgsbilanz: Information on Weihui Shao's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further research would be required to provide a detailed assessment.
GNNSF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading in these securities is often characterized by high risk and volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low liquidity can make it difficult to exit positions.
- Higher price volatility compared to exchange-listed stocks.
- Potential for manipulation due to limited regulatory oversight.
- OTC Other stocks may be subject to delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Scrutinize the company's financials, if available, and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Be aware of the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 2002.
- Genscript Biotech Corporation has a significant number of employees (5568).
- The company has a market capitalization of $3.41 billion.
- Genscript Biotech Corporation has a global presence with operations in multiple regions.
- The company operates in the biotechnology industry, which is subject to regulatory oversight.
Haeufige Fragen zu GNNSF
What are the key factors to evaluate for GNNSF?
Genscript Biotech Corporation (GNNSF) currently holds an AI score of 58/100, indicating moderate score. Key strength: Diverse service offerings across multiple segments of the biotechnology industry.. Primary risk to monitor: Potential: Regulatory hurdles and delays in drug approvals.. This is not financial advice.
How frequently does GNNSF data refresh on this page?
GNNSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNNSF's recent stock price performance?
Recent price movement in Genscript Biotech Corporation (GNNSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse service offerings across multiple segments of the biotechnology industry.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNNSF overvalued or undervalued right now?
Determining whether Genscript Biotech Corporation (GNNSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNNSF?
Before investing in Genscript Biotech Corporation (GNNSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNNSF to a portfolio?
Potential reasons to consider Genscript Biotech Corporation (GNNSF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse service offerings across multiple segments of the biotechnology industry.. Additionally: Global presence and established customer base.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GNNSF?
Yes, most major brokerages offer fractional shares of Genscript Biotech Corporation (GNNSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GNNSF's earnings and financial reports?
Genscript Biotech Corporation (GNNSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GNNSF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- AI analysis is pending for GNNSF, limiting the availability of analyst insights.
- Information on Weihui Shao's background and track record is limited.